The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Amedica/US Spine and Predictive Biosciences announced licensing and distribution deals with a pair of other companies.
Salt Lake City-based spinal reconstruction implant maker Amedica/US Spine intends to distribute spinal fusion, adhesion barrier and nerve protection products based on BioDlogics’ human cellular and tissue-based products, or allografts.
Predictive Biosciences completed a $25 million Series C round, saying it plans to use the money to complete clinical trials for its CertNDx bladder cancer assay and ready it for market.
Predictive Biosciences appointed two vice presidents and expanded its sales force as it prepares for the launch of a bladder cancer test.
James Groves was hired as vice president of lab operations and Mark Smith as vice president of information technology. Groves will help oversee Predictive’s OncoDiagnostic Laboratory, the company’s Cleveland-based commercial division and a recent acquisition. Smith is the former VP of information technology at Worcester, Mass.-based Athena Diagnostics.
Predictive Biosciences tapped veteran diagnostics industry executive Kim Blickenstaff, president and CEO of insulin pump developer Tandem Diabetes Care Inc., for its board of directors.
The Lexington, Mass-based cancer diagnostics developer said Blickenstaff’s expertise will come in handy as it readies to bring a non-invasive molecular diagnostic for bladder cancer to market via a recent acquisition.
Predictive Biosciences acquired molecular diagnostics firm OncoDiagnostic Laboratory for an undisclosed amount.
Cleveland-based ODL provides anatomic pathology and molecular diagnostics lab services to urologists, gastroenterologists, dermatologists, gynecologists and other subspecialty physicians nationwide. Lexington, Mass.-based Predictive Biosciences makes biomarkers, clinical algorithms and diagnostic assays designed to detect cancer.
